Suppliers / Nanjing King-Friend Biochemical Pharmaceutical

Nanjing King-Friend Biochemical Pharmaceutical

China 10 employees Updated 9 July 2026

Nanjing King-Friend Biochemical Pharmaceutical is a finished-dose manufacturer based in China. It holds 2 active US drug master files across a filed portfolio of 2 molecules. Its filings concentrate with NPRA (MY), EDE (AE) and ARCSA (EC). Its GMP standing is certified by ANVISA (Brazil), MHRA (UK) and EMA, among 4 authorities. Its most recent recorded inspection, by US FDA, closed on 14 March 2025 as NAI.

2
active US DMFs
0
valid CEPs
5
registered plants 1 with an FDA FEI number
18
filings across 5 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
6 of 6 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 14 March 2025 NAI US FDA
  • 23 March 2018 NAI US FDA
  • 15 May 2015 VAI US FDA
  • 21 December 2012 VAI US FDA
  • 21 October 2010 NAI US FDA
  • 4 September 2009 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Nanjing, United Arab Emirates Not on file
Nanjing, United Arab Emirates Not on file
NANJING, China Not on file
NANJING, China Not on file
China, China 3004664441

What they file, and where

Molecule Regulators Docs
Enoxaparin US FDA 1
Heparin Sodium US FDA 1

Also appears on these molecule pages

Enoxaparin contract manufacturing Fulvestrant finished dose Heparin contract manufacturing

Filings and GMP by regulator

Regulator Filings GMP certificates
NPRA (MY) 12 None
EDE (AE) 2 None
ARCSA (EC) 2 None
JFDA (JO) 1 None
UZPHARM (UZ) 1 None
ANVISA (Brazil) None 3
MHRA (UK) None 3
EMA None 1
US FDA None 1

Questions about Nanjing King-Friend Biochemical Pharmaceutical

Does Nanjing King-Friend Biochemical Pharmaceutical hold a US DMF or a CEP?
Nanjing King-Friend Biochemical Pharmaceutical holds 2 active US drug master files. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Nanjing King-Friend Biochemical Pharmaceutical FDA-registered?
One site operated by Nanjing King-Friend Biochemical Pharmaceutical carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Nanjing King-Friend Biochemical Pharmaceutical's last inspection go?
The most recent inspection on record closed on 14 March 2025 as NAI (No Action Indicated: nothing objectionable was found). 6 inspections are on file.
Where does Nanjing King-Friend Biochemical Pharmaceutical manufacture?
5 registered sites are on record, in United Arab Emirates and China (Nanjing, Nanjing and China among others). Every site is listed on this page with the register it came from.
What does Nanjing King-Friend Biochemical Pharmaceutical make?
2 molecules are on record against Nanjing King-Friend Biochemical Pharmaceutical, including Enoxaparin and Heparin Sodium. Each links through to that molecule's full manufacturer list.
Which regulators recognise Nanjing King-Friend Biochemical Pharmaceutical's GMP?
Current GMP certificates are on record from ANVISA (Brazil), MHRA (UK), EMA and US FDA. GMP recognition covers the manufacturing site, separately from any filing on the substance itself.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Nanjing King-Friend Biochemical Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 14 March 2025.

Comparable suppliers

Gland Pharma shares 2 molecules Dongying Tiandong Pharmaceutical shares 2 molecules Hebei Changshan Biochemical Pharmaceutical shares 2 molecules Hubei Enoray Biopharmaceutical shares 2 molecules Yantai Dongcheng Biochemicals Co.,Ltd shares 2 molecules

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates